Arrowhead Pharmaceuticals Inc (ARWR)
Return on equity (ROE)
| Sep 30, 2024 | Sep 30, 2023 | Sep 30, 2022 | Sep 30, 2021 | Sep 30, 2020 | ||
|---|---|---|---|---|---|---|
| Net income | US$ in thousands | -599,493 | -205,275 | -176,063 | -140,848 | -84,553 |
| Total stockholders’ equity | US$ in thousands | 185,444 | 271,343 | 398,520 | 408,822 | 461,779 |
| ROE | -323.27% | -75.65% | -44.18% | -34.45% | -18.31% |
September 30, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $-599,493K ÷ $185,444K
= -323.27%
Arrowhead Pharmaceuticals Inc's return on equity (ROE) has exhibited a declining trend over the past five years. The ROE decreased from -18.31% in 2020 to -323.27% in 2024, indicating a significant deterioration in the company's ability to generate profits relative to shareholder equity. This negative ROE suggests that Arrowhead Pharmaceuticals Inc has been consistently incurring net losses, resulting in a negative impact on shareholder value. The consecutive decline in ROE highlights challenges in profitability and operational efficiency within the company. Further analysis of the company's financial performance and strategic initiatives is recommended to address these concerning trends and improve ROE in the future.
Peer comparison
Sep 30, 2024